China, which now conducts more clinical drug trials than the U.S., still lags in several key areas of biotechnology innovation, according to a recent survey of senior U.S. leaders in industry and academia. The ​poll, conducted by Cure Innovation Index, found that China is seen as the clear leader in ‌two out of six sectors: clinical development and supply chain. It found that the U.S. leads in technology transfer, capital and commercialization and talent. The two countries were viewed as tied in the domain of scientific discovery. “The U.S. is still leading, but confidence is eroding. ​Most said they see China as an existential threat,” said Seema Kumar, CEO at Cure, which is ​an affiliate of investment firm Deerfield Management. The survey findings were presented in San Diego ⁠on Monday at the annual meeting of the Biotechnology Innovation Organization. In recent years, multinational pharmaceutical companies have augmented their pipelines ​with candidates developed in China, where costs are low, regulation is streamlined and some say government subsidies, opens new tab offer an unfair ​advantage.

Full sruvey : China, which now conducts more clinical drug trials than the U.S., still lags in several key areas of biotechnology innovation.